The Mass Balance Study of LP-168 in Healthy Subjects

NCT ID: NCT06126861

Last Updated: 2024-03-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-25
• Study Completion Date: 2024-03-13

Brief Summary

This study is a single-center, open-label, single-dose clinical pharmacokinetic study. The purpose of this study is to investigate the absorption characteristics, as well as to evaluate the metabolism and elimination pathways after a single oral dose of 150mg, 100μCi [14C]LP-168 in healthy subjects.

Conditions

Clinical Pharmacology

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

[14C]LP-168

Using 14C-labeled LP-168 as a marker to investigate the absorption characteristic, as well as to evaluate the metabolism and elimination pathways in healthy subjects

Group Type: EXPERIMENTAL

[14C]LP-168

Intervention Type: DRUG

single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state

Interventions

[14C]LP-168

single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy male subjects
• Aged 18-45 (including the boundary value);
• Body weight over 50 kg, the body mass index (BMI) is between 19 and 26 kg/m2 (including the boundary value);
• Subjects must sign the informed consent form voluntarily;
• Agree to abide the requirements of the study protocol, willing to communicate with the study doctor.

Exclusion Criteria

• After a comprehensive physical examination, vital signs, laboratory tests and other examinations are abnormal and have clinical significance;
• Hepatitis B surface antigen or E antigen, hepatitis C virus antibody IgG (Anti-HCV IgG), human immunodeficiency virus antigen/antibody combined test (HIV-Ag/Ab) and Treponema pallidum antibody test positive;
• Subject with clinically significant abnormalities on ophthalmologic examination (slit lamp, intraocular pressure and fundus photography)
• Subject who have used any drug that inhibits or induces hepatic drug metabolizing enzymes or transporters during the screening period and within the previous 28 days;
• Subject who have taken any medication with inhibition gastric acid secretion during the screening period and within the previous 28 days
• Subject who have taken any anti-gastric acid medication during the screening period and within the previous 28 days
• Subject who have used any systemic medication during the screening period and within the previous 14 days
• Subject with a history of any clinically serious illness or disease or condition that, in the opinion of the investigator, may affect the results of the trial
• Subject with any condition that may affect the absorption of the drug
• Subject with history of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, ventricular tachycardia, atrioventricular block, QT prolongation syndrome, or symptoms of QT prolongation syndrome or family history of these syndrome.
• Subject with major surgery during the screening period and within the previous 6 months or surgical incisions that have not fully healed
• Subject with allergies, such as a known history of allergy to two or more substances
• Subject with hemorrhoids or perianal disease with regular or ongoing blood in the stool, irritable bowel syndrome, inflammatory bowel disease
• Subject with habitual constipation or diarrhea
• Subject with alcohol abuse or regular use of alcohol in the 6 months prior to the screening period
• Subject with smoking >5 cigarettes per day before the first 3 months of the screening period
• Subject with drug abuse
• Subject who are subjected to long-term exposure to radioactive conditions
• Subject who have difficulty collecting blood or cannot tolerate venipuncture for blood collection
• Subject with participation in any other clinical trial during the screening period and within the previous 3 months
• Subject who have been vaccinated during the screening period and within the previous 1 month or who are scheduled to be vaccinated during the trial period
• Subject with plans to have children or donate sperm during the trial and within 1 year after completion of the trial
• Subject who had lost or donated up to 400 mL of blood during the screening period and within the previous 3 months, or those who had received a blood transfusion within 1 month;
• Subject with any factors that the investigator believes make participation in this trial inappropriate

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Guangzhou Lupeng Pharmaceutical Company LTD.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Liyan Miao, MD

Role: PRINCIPAL_INVESTIGATOR

The First Affiliated Hospital of Soochow University

Locations

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Countries

China

Other Identifiers

LP-168-CN104

Identifier Type: -

Identifier Source: org_study_id